Related Experiment Video
Updated: Jul 13, 2025
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Mathematical analysis identifies the optimal treatment strategy for epidermal growth factor receptor-mutated
Qian Yu1, Susumu S Kobayashi2, Hiroshi Haeno3
1Department of Computational Biology and Medical Sciences, Graduate School of Frontier Science, The University of Tokyo, Kashiwa, Japan.
Introduction:
In Asians, more than half of non-small cell lung cancers (NSCLC) are induced by epidermal growth factor receptor (EGFR) mutations. Although patients carrying EGFR driver mutations display a good initial response to EGFR-Tyrosine Kinase Inhibitors (EGFR-TKIs), additional mutations provoke drug resistance. Hence, predicting tumor dynamics before treatment initiation and formulating a reasonable treatment schedule is an urgent challenge.
Methods:
To overcome this problem, we constructed a mathematical model based on clinical observations and investigated the optimal schedules for EGFR-TKI therapy.
Results:
Based on published data on cell growth rates under different drugs, we found that using osimertinib that are efficient for secondary resistant cells as the first-line drug is beneficial in monotherapy, which is consistent with published clinical statistical data. Moreover, we identified the existence of a suitable drug-switching time; that is, changing drugs too early or too late was not helpful. Furthermore, we demonstrate that osimertinib combined with erlotinib or gefitinib as first-line treatment, has the potential for clinical application. Finally, we examined the relationship between the initial ratio of resistant cells and final cell number under different treatment conditions, and summarized it into a therapy suggestion map. By performing parameter sensitivity analysis, we identified the condition where osimertinib-first therapy was recommended as the optimal treatment option.
Discussion:
This study for the first time theoretically showed the optimal treatment strategies based on the known information in NSCLC. Our framework can be applied to other types of cancer in the future.
Insights
Optimizing epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for non-small cell lung cancer (NSCLC) is crucial. This study models treatment schedules, recommending osimertinib-first therapy for improved outcomes in EGFR-mutated NSCLC.
Area of Science:
- Oncology
- Mathematical Biology
- Pharmacology
Background:
- Epidermal growth factor receptor (EGFR) mutations drive over half of non-small cell lung cancers (NSCLC) in Asian populations.
- While EGFR-tyrosine kinase inhibitors (TKIs) initially benefit patients with EGFR-mutated NSCLC, acquired resistance due to secondary mutations poses a significant clinical challenge.
- Predicting tumor dynamics and optimizing EGFR-TKI treatment schedules are critical for improving patient outcomes.
Purpose of the Study:
- To develop a mathematical model for investigating optimal EGFR-TKI therapy schedules in NSCLC.
- To identify effective monotherapy and combination therapy strategies for EGFR-mutated NSCLC.
- To provide a theoretical framework for personalized NSCLC treatment based on tumor characteristics.
Main Methods:
- Construction of a mathematical model integrating clinical data on cell growth rates under various drug treatments.
- Analysis of drug efficacy, optimal drug-switching times, and combination therapy potential.
- Parameter sensitivity analysis to determine the most effective treatment conditions.
Main Results:
- Osimertinib, effective against secondary resistant cells, is beneficial as a first-line monotherapy, aligning with clinical observations.
- A specific drug-switching time was identified as crucial; premature or delayed switching is detrimental.
- Combination therapies (osimertinib with erlotinib or gefitinib) show potential for clinical application.
- A therapy suggestion map was created based on initial resistant cell ratios and treatment outcomes.
- Osimertinib-first therapy was identified as the optimal strategy under specific conditions.
Conclusions:
- This study provides the first theoretical basis for optimal treatment strategies in EGFR-mutated NSCLC.
- The developed framework offers a potential approach for optimizing cancer therapies in other malignancies.
- Personalized treatment scheduling based on mathematical modeling can improve the efficacy of EGFR-TKI therapy in NSCLC.
More Related Videos
13:34A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Related Concept Videos
02:38Mitogens and the Cell Cycle
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...